Protara Therapeutics, Inc. (TARA) investor relations documents from the company's IR site: 2 presentations; latest deck 2025-04-23. Read in-app with summaries. First-party data.
AUA poster: Preliminary Efficacy and Safety Results From ADVANCED-2: A Phase-2 Open-label Study of Intravesical TARA-002: Phase 2 ADVANCED-2 study data for TARA-002 in high-risk NMIBC shows a 100% complete response rate in BCG-unresponsive patients and 76% in BCG-naïve patients.
| Published | Type | Document |
|---|---|---|
| 2025-04-23 | Presentation | AUA poster: Preliminary Efficacy and Safety Results From ADVANCED-2: A Phase-2 Open-label Study of Intravesical TARA-002 |
| 2025-03-24 | Presentation | ASPEN 2025 Oral Presentation – THRIVE-1: A multi-center, cross-sectional, observational study to assess the prevalence o |
TARA overview · TARA earnings · TARA financials · TARA KPIs · TARA ownership · TARA peers · TARA filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.